

# Ankhos Oncology Software

Real World Testing Results Report CY 2023

## General Information

Plan Report ID Number: 20221108ank

Developer Name: Ankhos Oncology Software

Product Name(s):Ankhos

Version Number(s): 4

Certified Health IT Product List (CHPL) Product Number(s): 15.05.05.2959.ANKH.01.00.0.210111

Developer Real World Testing Plan Page URL: <https://www.ankhos.com/real-world-testing>

Developer Real World Testing Results Report Page URL: <https://www.ankhos.com/real-world-testing>

## Changes to Original Plan

No changes were made to the original test plan

## Withdrawn Products

None

## Summary of Testing Methods and Key Findings

### Testing experience

There were multiple key findings from obtained while conducting Ankhos RWT. Results were obtained with a combination of queries, as well as visual validation of those queries. For some tests, manual document validation was required.

### Challenges and lessons learned

Calendar year 2023 saw dramatic improvement in the number of valid CCDA files received. This is likely due to wider adoption as well as measures put in place to accommodate wider parsing of non-CCDA-compliant documents received.

There were few Direct messages that contained .rtf files or unsolicited HL7v2 content.

Even with these challenges in mind, we continue to demonstrate that users are actively using the CCDA import functionality as a consistent percentage of CCDA documents were being imported and integrated into the medical record.

One challenge remains: that CCDA documents are provided for patients who are not a part of the practice. In these cases the messages are archived as they are not able to be incorporated into the medical record.

Non-conformance

No non-conformities were identified during testing.

## Standards Updates (SVAP and USCDI)

<b>Standard (and version)</b>	USCDI v1
<b>Updated certification criteria and associated product</b>	b2
<b>Health IT Module CHPL ID</b>	15.05.05.2959.ANKH.01.00.0.210111
<b>Method used for standard update</b>	Cures Update
<b>Date of ONC ACB notification</b>	11/21/2022
<b>Date of customer notification (SVAP only)</b>	N/A
<b>Conformance measure</b>	Measures B2.1, B2.2, B2.3
<b>USCDI updated certification criteria (and USCDI version)</b>	b2 - USCDI v1

## Care Settings

All real-world data are observed from outpatient clinical oncology practices.

## Metrics and Outcomes by measure

Below are utilization numbers by quarter for each metric. Conclusions and observations are listed below.

Metric	Q1 2023	Q2 2023	Q3 2023	Q4 2023
B2.1 CCDA documents received	187	202	125	111
B2.2 CCDA documents successfully parsed	100% (187)	100% (202)	100% (125)	100% (111)
B2.3 CCDA documents imported	95% (178)	89% (181)	91% (114)	87% (97)
C1.1 QRDA documents exported	None, sample QRDA File Validated	None, sample QRDA File Validated	None, sample QRDA File Validated	None, sample QRDA File Validated
F1.1 Immunization cases reported	None, test Immunization case created	None, test Immunization case created	None, test Immunization case created	None, test Immunization case created
F4.1 Cancer cases exported	None, sample Cancer case file generated	None, sample Cancer case file generated	None, sample Cancer case file generated	None, sample Cancer case file generated

### B2 observations and conclusions

Key Metrics:

- B2.1 CCDA documents received
- B2.2 CCDA documents successfully parsed
- B2.3 CCDA documents imported

Associated Criteria: B2

Relied upon software: None

Outcomes:

Customers are successfully receiving and incorporating CCDA R2.1 files via Direct messaging. In some cases, incoming Direct messages did not include CCDA files. Messaging including ONLY .RTF files, were not imported as they did not contain sufficient metadata to parse.

Further, in some cases, incoming files did not match new or existing patients and were archived.

No invalid CCDA files were encountered during RWT compilation.

Challenges: It was necessary to differentiate between Direct messages that did and did not contain CCDA files. All messages that did contain CCDA files were able to be parsed.

## C1 Observations and Conclusions:

### Key Metrics:

- C1.1 QRDA documents exported

Associated Criteria: C1

Relied upon software: None

Outcomes:

No practices manually exported QRDA files for the testing periods. Sample QRDA files were generated successfully.

Challenges: None

## F1 Observations and Conclusions

### Key Metrics:

- F1.1 Immunization cases reported

Associated criteria: F1

No practices submitted real-world immunization cases through Ankhos during the testing periods. A sample immunization case was created successfully.

## F4 Observations and Conclusions

### Key Metrics:

- F4.1 Cancer cases exported

Associated Criteria: F4

Relied upon software: None

Outcomes:

No practices submitted cancer case files during the testing periods. Test Cancer submission files were generated successfully.

Challenges: None

## Key Milestones

Data were compiled for each calendar quarter in 2023. In all cases, the setting was in the context of outpatient medical oncology.